Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Markets and Markets to hold a virtual event » 09:46
06/25/20
06/25
09:46
06/25/20
09:46
ALLO

Allogene Therapeutics

$43.29 /

+ (+0.00%)

, CELG

Bought by BMY

$108.26 /

+ (+0.00%)

, MRK

Merck

$75.62 /

-0.22 (-0.29%)

, PFE

Pfizer

$32.09 /

-0.11 (-0.34%)

, QGEN

Qiagen

$43.07 /

+0.1 (+0.23%)

, REGN

Regeneron

$608.77 /

+3.675 (+0.61%)

, TAK

Takeda Pharmaceutical

$18.25 /

-0.08 (-0.44%)

Next-Gen 3rd Annual…

Next-Gen 3rd Annual Immuno-Oncology Virtual Congress will be held on June 25-26. Webcast Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

CELG Bought by BMY
$108.26 /

+ (+0.00%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

06/08/20 SunTrust
Allogene Therapeutics price target raised to $50 from $32 at SunTrust
06/01/20
Fly Intel: Top five analyst downgrades
06/01/20 Oppenheimer
Allogene Therapeutics price target raised to $55 from $50 at Oppenheimer
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
CELG Bought by BMY
$108.26 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
MRK Merck
$75.62 /

-0.22 (-0.29%)

06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
PFE Pfizer
$32.09 /

-0.11 (-0.34%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
REGN Regeneron
$608.77 /

+3.675 (+0.61%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

CELG Bought by BMY
$108.26 /

+ (+0.00%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

Hot Stocks
Allogene says preclinical findings support DLL3-targeted AlloCAR-T in SCLC » 16:34
06/22/20
06/22
16:34
06/22/20
16:34
ALLO

Allogene Therapeutics

$42.73 /

+2.7 (+6.74%)

Allogene Therapeutics…

Allogene Therapeutics announced that preclinical findings supporting DLL3-targeted AlloCAR T therapy in small cell lung cancer, or SCLC, and inducible TurboCAR technology were presented in poster sessions at the virtual American Association for Cancer Research annual meeting. In research featured during the virtual meeting, genetically modified T cells expressing chimeric antigen receptors targeting Delta-like ligand 3 were screened, characterized and ranked against targets using in vitro cytotoxicity assays. Highly active DLL3 CARs displaying long-term killing potential were engineered to contain a rituximab off-switch. Lead DLL3 candidates were tested in vivo and robust efficacy was observed in both subcutaneous and systemic models of SCLC. Additionally, while DLL3 RNA has normal tissue expression in the brain, pituitary and testis, toxicity studies using subcutaneous and intracranial tumor models showed no tissue damage in the brain or pituitary. In a second poster, researchers presented data on a version of Allogene's TurboCAR technology that allows cytokine activation signaling to be selectively controlled by a small-molecule on-switch. This iTurboCAR can be activated by a clinically validated dimerizer drug to improve the potency and persistence of CAR T cells.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$42.73 /

+2.7 (+6.74%)

ALLO Allogene Therapeutics
$42.73 /

+2.7 (+6.74%)

06/08/20 SunTrust
Allogene Therapeutics price target raised to $50 from $32 at SunTrust
06/01/20
Fly Intel: Top five analyst downgrades
06/01/20 Oppenheimer
Allogene Therapeutics price target raised to $55 from $50 at Oppenheimer
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
ALLO Allogene Therapeutics
$42.73 /

+2.7 (+6.74%)

ALLO Allogene Therapeutics
$42.73 /

+2.7 (+6.74%)

Hot Stocks
Allogene Therapeutics announces publication highlighting ALLO-819 potential » 08:45
06/22/20
06/22
08:45
06/22/20
08:45
ALLO

Allogene Therapeutics

$40.03 /

-1.765 (-4.22%)

Allogene Therapeutics…

Allogene Therapeutics announced a publication in Molecular Therapy demonstrating the potential for ALLO-819, an investigational AlloCAR T therapy targeting FLT3 as a novel treatment for acute myeloid leukemia. These preclinical findings were previously presented as a poster at the 61st American Society of Hematology Annual Meeting & Exposition in December 2019. In this study, healthy donor T lymphocytes were engineered to express CARs that bound to different domains of the FLT3 protein. These CARs were then tested for their ability to mediate specific killing of FLT3-expressing cells without off-target activity. A CAR construct was selected based on exhibiting minimal potential for exhaustion and potent antitumor activity in vitro and in vivo models.The lead candidate was then engineered to contain an off-switch responsive to rituximab, resulting in ALLO-819.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$40.03 /

-1.765 (-4.22%)

ALLO Allogene Therapeutics
$40.03 /

-1.765 (-4.22%)

06/08/20 SunTrust
Allogene Therapeutics price target raised to $50 from $32 at SunTrust
06/01/20
Fly Intel: Top five analyst downgrades
06/01/20 Oppenheimer
Allogene Therapeutics price target raised to $55 from $50 at Oppenheimer
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
ALLO Allogene Therapeutics
$40.03 /

-1.765 (-4.22%)

ALLO Allogene Therapeutics
$40.03 /

-1.765 (-4.22%)

Hot Stocks
Revolution Medicines appoints Eric Shmidt, Peter Svennilson to board » 07:47
06/18/20
06/18
07:47
06/18/20
07:47
RVMD

Revolution Medicines

$36.66 /

-1.27 (-3.35%)

, ALLO

Allogene Therapeutics

$41.95 /

-0.085 (-0.20%)

Revolution Medicines…

Revolution Medicines (RVMD) announced the appointments of Eric Schmidt, Ph.D., and Peter Svennilson to its board of directors. Mr. Svennilson was appointed to fill the vacancy created by the resignation of Larry Lasky, Ph.D., who stepped down from the board of directors and will continue supporting the company as a scientific advisor. Schmidt currently serves as the chief financial officer of Allogene Therapeutics (ALLO). Svennilson founded The Column Group in 2007 and has worked in venture capital and finance for more than 35 years.

ShowHide Related Items >><<
RVMD Revolution Medicines
$36.66 /

-1.27 (-3.35%)

ALLO Allogene Therapeutics
$41.95 /

-0.085 (-0.20%)

RVMD Revolution Medicines
$36.66 /

-1.27 (-3.35%)

05/21/20
Fly Intel: Top five analyst initiations
05/21/20 H.C. Wainwright
Revolution Medicines initiated with a Buy at H.C. Wainwright
03/09/20
Fly Intel: Top five analyst initiations
03/09/20 Cowen
Revolution Medicines initiated with an Outperform at Cowen
ALLO Allogene Therapeutics
$41.95 /

-0.085 (-0.20%)

06/08/20 SunTrust
Allogene Therapeutics price target raised to $50 from $32 at SunTrust
06/01/20
Fly Intel: Top five analyst downgrades
06/01/20 Oppenheimer
Allogene Therapeutics price target raised to $55 from $50 at Oppenheimer
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
ALLO Allogene Therapeutics
$41.95 /

-0.085 (-0.20%)

RVMD Revolution Medicines
$36.66 /

-1.27 (-3.35%)

ALLO Allogene Therapeutics
$41.95 /

-0.085 (-0.20%)

Recommendations
Allogene Therapeutics price target raised to $50 from $32 at SunTrust » 09:09
06/08/20
06/08
09:09
06/08/20
09:09
ALLO

Allogene Therapeutics

$42.67 /

-0.27 (-0.63%)

SunTrust analyst Asthika…

SunTrust analyst Asthika Goonewardene raised the firm's price target on Allogene Therapeutics to $50 from $32 and keeps a Hold rating on the shares. ALPHA is delivering as it was intended to "by characterizing the expansion profile and lymphodepletion dynamics", the analyst tells investors in a research note. Goonewardene adds his new price target reflects his updated view on the potential of ALLO-501A in follicular lymphoma and ALLO-715 in multiple myeloma.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$42.67 /

-0.27 (-0.63%)

ALLO Allogene Therapeutics
$42.67 /

-0.27 (-0.63%)

06/01/20
Fly Intel: Top five analyst downgrades
06/01/20 Oppenheimer
Allogene Therapeutics price target raised to $55 from $50 at Oppenheimer
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
06/01/20 Goldman Sachs
Allogene Therapeutics price target raised to $66 from $45 at Goldman Sachs
ALLO Allogene Therapeutics
$42.67 /

-0.27 (-0.63%)

ALLO Allogene Therapeutics
$42.67 /

-0.27 (-0.63%)

Over a month ago
Syndicate
Allogene Therapeutics 11.7M share Secondary priced at $47.00 » 06:21
06/02/20
06/02
06:21
06/02/20
06:21
ALLO

Allogene Therapeutics

$48.94 /

+0.86 (+1.79%)

The deal size was…

The deal size was increased to $550M in common stock from $450M in common stock. Goldman Sachs, Jefferies and Cowen acted as joint book running managers for the offering.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$48.94 /

+0.86 (+1.79%)

ALLO Allogene Therapeutics
$48.94 /

+0.86 (+1.79%)

06/01/20
Fly Intel: Top five analyst downgrades
06/01/20 Oppenheimer
Allogene Therapeutics price target raised to $55 from $50 at Oppenheimer
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
06/01/20 Goldman Sachs
Allogene Therapeutics price target raised to $66 from $45 at Goldman Sachs
ALLO Allogene Therapeutics
$48.94 /

+0.86 (+1.79%)

  • 02
    Jun
ALLO Allogene Therapeutics
$48.94 /

+0.86 (+1.79%)

Downgrade
Fly Intel: Top five analyst downgrades » 10:06
06/01/20
06/01
10:06
06/01/20
10:06
ABT

Abbott

$93.00 /

-2.31 (-2.42%)

, ALLO

Allogene Therapeutics

$46.37 /

-1.71 (-3.56%)

, MTN

Vail Resorts

$196.72 /

-1.8 (-0.91%)

, CGC

Canopy Growth

$16.50 /

-0.885 (-5.09%)

, AER

AerCap

$32.28 /

+ (+0.00%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Abbott (ABT) downgraded to Sell from Neutral at Goldman Sachs with analyst Amit Hazan saying the stock has overreacted to the company's COVID testing opportunity. 2. Allogene Therapeutics (ALLO) downgraded to Market Perform at Raymond James with analyst Dane Leone saying the ASCO 2020 dataset for ALLO-501 has validated his investment hypothesis and the stock price now exceeds the prior $40 price target. 3. Vail Resorts (MTN) downgraded to Hold from Buy at Deutsche Bank with analyst Chris Woronka saying he believes the "recovery trade" in cyclicals like Vail may be close to stalling and sees a balanced risk/reward profile with the shares near the price target. 4. Canopy Growth (CGC) was downgraded to Sell from Buy at Stifel, to Sell from Neutral at Bryan Garnier and PI Financial, to Neutral from Outperformer at CIBC, and to Market Perform from Outperform at BMO Capital. 5. AerCap (AER) downgraded to Neutral from Buy at BofA with analyst Ronald Epstein saying the stock's material underperformance since early March has been driven by concerns and uncertainties over the future of air travel post-pandemic and the company's older fleet may be under pressure in the current environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
MTN Vail Resorts
$196.72 /

-1.8 (-0.91%)

CGC Canopy Growth
$16.50 /

-0.885 (-5.09%)

ALLO Allogene Therapeutics
$46.37 /

-1.71 (-3.56%)

AER AerCap
$32.28 /

+ (+0.00%)

ABT Abbott
$93.00 /

-2.31 (-2.42%)

ABT Abbott
$93.00 /

-2.31 (-2.42%)

05/31/20 Goldman Sachs
Abbott downgraded to Sell from Neutral at Goldman Sachs
04/20/20 Barclays
Abbott price target raised to $100 from $92 at Barclays
04/20/20 Barclays
Abbott price target raised to $100 from $92 at Barclays
04/17/20 Raymond James
Abbott price target raised to $102 from $92 at Raymond James
ALLO Allogene Therapeutics
$46.37 /

-1.71 (-3.56%)

06/01/20 Oppenheimer
Allogene Therapeutics price target raised to $55 from $50 at Oppenheimer
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
06/01/20 Goldman Sachs
Allogene Therapeutics price target raised to $66 from $45 at Goldman Sachs
06/01/20 JMP Securities
Allogene Therapeutics price target raised to $53 from $37 at JMP Securities
MTN Vail Resorts
$196.72 /

-1.8 (-0.91%)

06/01/20 Deutsche Bank
Vail Resorts downgraded to Hold on valuation at Deutsche Bank
05/31/20 Deutsche Bank
Vail Resorts downgraded to Hold from Buy at Deutsche Bank
05/21/20 Credit Suisse
Vail Resorts initiated with an Outperform at Credit Suisse
04/28/20 Deutsche Bank
Vail Resorts price target raised to $197 from $183 at Deutsche Bank
CGC Canopy Growth
$16.50 /

-0.885 (-5.09%)

06/01/20 Alliance Global Partners
Canopy Growth price target lowered to C$24 from C$30 at Alliance Global Partners
06/01/20 BMO Capital
Canopy Growth downgraded to Market Perform from Outperform at BMO Capital
06/01/20 CIBC
Canopy Growth downgraded to Neutral from Outperformer at CIBC
06/01/20 Stifel
Stifel double downgrades Canopy Growth to Sell on 'course correction'
AER AerCap
$32.28 /

+ (+0.00%)

06/01/20 BofA
AerCap downgraded to Neutral from Buy at BofA
05/27/20 Stephens
AerCap shouldn't need capital markets funding until 2021, says Stephens
05/26/20 JPMorgan
JPMorgan upgrades Fly Leasing with stock rally lagging peers
05/06/20 Deutsche Bank
AerCap price target lowered to $44 from $63 at Deutsche Bank
MTN Vail Resorts
$196.72 /

-1.8 (-0.91%)

CGC Canopy Growth
$16.50 /

-0.885 (-5.09%)

ALLO Allogene Therapeutics
$46.37 /

-1.71 (-3.56%)

AER AerCap
$32.28 /

+ (+0.00%)

ABT Abbott
$93.00 /

-2.31 (-2.42%)

MTN Vail Resorts
$196.72 /

-1.8 (-0.91%)

CGC Canopy Growth
$16.50 /

-0.885 (-5.09%)

AER AerCap
$32.28 /

+ (+0.00%)

ABT Abbott
$93.00 /

-2.31 (-2.42%)

MTN Vail Resorts
$196.72 /

-1.8 (-0.91%)

CGC Canopy Growth
$16.50 /

-0.885 (-5.09%)

ALLO Allogene Therapeutics
$46.37 /

-1.71 (-3.56%)

ABT Abbott
$93.00 /

-2.31 (-2.42%)

MTN Vail Resorts
$196.72 /

-1.8 (-0.91%)

CGC Canopy Growth
$16.50 /

-0.885 (-5.09%)

AER AerCap
$32.28 /

+ (+0.00%)

ABT Abbott
$93.00 /

-2.31 (-2.42%)

Recommendations
Allogene Therapeutics price target raised to $55 from $50 at Oppenheimer » 07:50
06/01/20
06/01
07:50
06/01/20
07:50
ALLO

Allogene Therapeutics

$48.08 /

+1.48 (+3.18%)

Oppenheimer analyst Mark…

Oppenheimer analyst Mark Breidenbach raised the firm's price target on Allogene Therapeutics to $55 from $50 and keeps an Outperform rating on the shares. The analyst notes that Allogene presented initial results from its ALPHA trial of ALLO-501 in an oral presentation at ASCO. Breidenbach believes ALLO-501's clinical profile should be construed as an ominous sign for autologous CD19 CAR-Ts, and provides a strong foundation heading into the potentially registrational ALPHA2 study.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
06/01/20 Goldman Sachs
Allogene Therapeutics price target raised to $66 from $45 at Goldman Sachs
06/01/20 JMP Securities
Allogene Therapeutics price target raised to $53 from $37 at JMP Securities
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform at Raymond James
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

Downgrade
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James » 07:46
06/01/20
06/01
07:46
06/01/20
07:46
ALLO

Allogene Therapeutics

$48.08 /

+1.48 (+3.18%)

Raymond James analyst…

Raymond James analyst Dane Leone downgraded Allogene Therapeutics to Market Perform from Outperform without a price target, saying the ASCO 2020 dataset for ALLO-501 has validated his investment hypothesis and the stock price now exceeds the prior $40 price target. Leone tells investors that Allogene has fully delivered on its proof of concept goal with the ASCO 2020 dataset, and management has built up credibility, but also thinks that providing a definitive comparison to autologous CAR+ T cell therapy will not be possible until the 90mg dosage group has sufficient follow-up and can then be supported by an initial dataset from the ALLO-501a study.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

06/01/20 Goldman Sachs
Allogene Therapeutics price target raised to $66 from $45 at Goldman Sachs
06/01/20 JMP Securities
Allogene Therapeutics price target raised to $53 from $37 at JMP Securities
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform at Raymond James
05/29/20 H.C. Wainwright
Allogene Therapeutics price target raised to $55 from $42 at H.C. Wainwright
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

Recommendations
Allogene Therapeutics price target raised to $66 from $45 at Goldman Sachs » 07:08
06/01/20
06/01
07:08
06/01/20
07:08
ALLO

Allogene Therapeutics

$48.08 /

+1.48 (+3.18%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter raised the firm's price target on Allogene Therapeutics to $66 from $45 and keeps a Buy rating on the shares after the company presented additional data from its Phase 1 allogeneic CAR T ALLO-501 study in relapsed/refractory non-Hodgkin's lymphoma. The analyst views the data as "highly encouraging" and believes it further de-risks Allogene's allogeneic CAR T platform.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

06/01/20 JMP Securities
Allogene Therapeutics price target raised to $53 from $37 at JMP Securities
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform at Raymond James
05/29/20 H.C. Wainwright
Allogene Therapeutics price target raised to $55 from $42 at H.C. Wainwright
05/29/20 Piper Sandler
Allogene Therapeutics price target raised to $70 from $50 at Piper Sandler
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.